Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial.

Overview

authors

Goodman, Shaun G

Steg, Philippe Gabriel

Bhatt, Deepak L

Bittner, Vera A

Garon, Genevieve

Harrington, Robert
Jukema, J Wouter
Manvelian, Garen
Stipek, Wanda
Szarek, Michael
White, Harvey D
Schwartz, Gregory G

publication date

September 13, 2023

published in

Journal of the American Heart Association Journal

Research

keywords

Antibodies, Monoclonal, Humanized

Identity

PubMed Central ID

PMC10547267

Scopus Document Identifier

85171790734

Digital Object Identifier (DOI)

10.1161/JAHA.122.029216

PubMed ID

37702079

Additional Document Info

has global citation frequency

20

volume

12

issue

18